Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Test della chemioterapia comune a basso dosaggio (doxorubicina liposomiale) in combinazione con un farmaco antitumorale, Peposertib, nel sarcoma avanzato

13 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio di fase 1 su Peposertib (M3814) e doxorubicina liposomiale a basso dosaggio (Doxil®) in pazienti con leiomiosarcoma metastatico e altri sarcomi dei tessuti molli

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of peposertib in combination with low-dose pegylated liposomal doxorubicin hydrochloride (liposomal doxorubicin) as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level.

II. To determine the recommended phase 2 dose (RP2D) of liposomal doxorubicin and peposertib combination and determine the maximal tolerated dose (MTD) if identified.

SECONDARY OBJECTIVE:

I. To assess the pharmacokinetics of peposertib and liposomal doxorubicin used in combination with each other.

CORRELATIVE OBJECTIVES:

I. To test the hypothesis that soft tissue sarcomas (STS) with homologous recombination deficiency (HRD) like leiomyosarcomas (LMS) will be more susceptible to DNA-protein kinase inhibitor (PKi) in combination with low-dose liposomal doxorubicin.

II. To test the hypothesis that gammaH2AX and pNBS1 can be used as pharmacodynamic biomarkers of response to DNA-PKi in combination with low-dose liposomal doxorubicin.

III. To test the hypothesis that disease activity correlates with circulating tumor DNA levels in the plasma.

OUTLINE: This is a dose-escalation study of peposertib and liposomal doxorubicin.

Patients receive peposertib orally (PO) twice daily (BID) on days 1-28 of each cycle and liposomal doxorubicin intravenously (IV) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients also undergo tissue biopsy and echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and on the trial.

Patients are followed for 30 days after removal from study or until death, whichever occurs first.

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • USC / Norris Comprehensive Cancer Center
        • Investigatore principale:
          • Mark Agulnik
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 323-865-0451
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • Los Angeles General Medical Center
        • Investigatore principale:
          • Mark Agulnik
        • Contatto:
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • UCHealth University of Colorado Hospital
        • Investigatore principale:
          • Breelyn A. Wilky
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 720-848-0650
    • Florida
      • Miami, Florida, Stati Uniti, 33136
        • Reclutamento
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • Investigatore principale:
          • Emily E. Jonczak
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 305-243-2647
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Attivo, non reclutante
        • University of Chicago Comprehensive Cancer Center
      • New Lenox, Illinois, Stati Uniti, 60451
        • Attivo, non reclutante
        • UC Comprehensive Cancer Center at Silver Cross
      • Orland Park, Illinois, Stati Uniti, 60462
        • Attivo, non reclutante
        • University of Chicago Medicine-Orland Park
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Reclutamento
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Contatto:
        • Investigatore principale:
          • H. Catherine Wilbur
      • Bethesda, Maryland, Stati Uniti, 20892
        • Reclutamento
        • National Cancer Institute Developmental Therapeutics Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-411-1222
        • Investigatore principale:
          • A P. Chen
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana-Farber Cancer Institute
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-442-3324
        • Investigatore principale:
          • Candace L. Haddox
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Sospeso
        • University of Michigan Rogel Cancer Center
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine
        • Investigatore principale:
          • Mia C. Weiss
        • Contatto:
      • St Louis, Missouri, Stati Uniti, 63129
        • Reclutamento
        • Siteman Cancer Center-South County
        • Investigatore principale:
          • Mia C. Weiss
        • Contatto:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • Reclutamento
        • UPMC Hillman Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 412-647-8073
        • Investigatore principale:
          • Melissa A. Burgess
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • UT MD Anderson Cancer Center
        • Contatto:
        • Investigatore principale:
          • Michael S. Nakazawa
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Reclutamento
        • University of Virginia Cancer Center
        • Contatto:
        • Investigatore principale:
          • Paul V. Viscuse

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients must have histologically confirmed sarcoma that is metastatic or unresectable and for which there is no known curative treatment

  • Patients must have histologic diagnosis of leiomyosarcoma (LMS) or selected soft tissue sarcomas (myxofibrosarcoma [MFS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma, or dedifferentiated liposarcoma [DDLPS]). Pathology review and confirmation of diagnosis will occur at the site enrolling the patient on this study. If the pathology has previously been reviewed by another site participating in the study, the diagnosis does not need to be re-reviewed at the enrolling site

  • Patients must have evaluable disease that is amenable to biopsy

  • Patients must have been treated with at least 1 prior line of therapy. Prior anthracycline use is permitted as long as the cumulative dose prior to enrollment does not exceed 360 mg/m^2

  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of peposertib (M3814) in combination with liposomal doxorubicin in patients < 18 years of age, children are excluded from this study

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,500/mcL

  • Platelets >= 100,000/mcL

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN

  • Hemoglobin >= 8 g/dL

  • Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 (per institutional estimate based on creatinine level)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and clinical symptoms are stable while off steroid support

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history of clinically significant cardiac disease, or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

    • Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin
  • Male patients of reproductive potential must agree to avoid impregnating a partner while receiving study drug and for 3 months after the last dose of peposertib (M3814) and 6 months after the last dose of liposomal doxorubicin by complying with adequate methods of contraception

    • Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia

  • Prior palliative radiotherapy within 14 days of cycle 1 day 1 and prior definitive radiotherapy within 42 days of cycle 1 day 1. Adverse effects of radiation therapy must resolve to baseline prior to cycle 1 day 1

  • Patients who are receiving any other investigational agents

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to peposertib (M3814) or other agents used in study

  • Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9, and CYP2C19. Participants who cannot discontinue substrates with a narrow therapeutic index that are metabolized by CYP1A2, CYP2B6, CYP2C8, and CYP3A4/5 are ineligible. Patients may confer with the study doctor to determine if alternative medications can be used. The following categories of medications and herbal supplements must be discontinued for at least the specified period of time before the patient can be treated:

    • Strong inducers of CYP3A4/5 and CYP2C19: >= 3 weeks prior to study treatment
    • Strong inhibitors of CYP3A4/5 and CYP2C19: >= 1 week prior to study treatment
    • Substrates of CYP3A4/5 with a narrow therapeutic index: >= 1 day prior to study treatment
    • Strong inhibitors of CYP2C9: >= 1 week prior to study treatment
  • Patients who cannot discontinue concomitant proton-pump inhibitors (PPIs). Patients may confer with the study doctor to determine if such medications can be discontinued. These must be discontinued >= 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate

  • Patients with left ventricular ejection fraction (LVEF) measurement below the institutional lower limit of normal (LLN) are excluded

  • Patients with uncontrolled intercurrent illness

  • Patients who cannot swallow tablets whole

  • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are not eligible

  • Pregnant women are excluded from this study because peposertib (M3814) is an adenosine triphosphate (ATP)-competitive inhibitor of DNA-protein kinase catalytic subunit (PKcs) with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with peposertib (M3814), breastfeeding should be discontinued if the mother is treated with peposertib (M3814). These potential risks may also apply to other agents used in this study

  • Patients may not have received prior treatment with a DNA-protein kinase (PK) inhibitor

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (peposertib, liposomal doxorubicin)

Patients receive peposertib PO BID on days 1-28 of each cycle and liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and CT or MRI throughout the trial. Patients also undergo tissue biopsy and ECHO or MUGA during screening and on the trial.

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Undergo MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo ECHO

Altri nomi:
  • Ecocardiografia
  • CE

Undergo MUGA

Altri nomi:
  • Scansione della pozza di sangue
  • Angiografia con radionuclidi di equilibrio
  • Imaging del pool di sangue recintato
  • MUGA
  • Ventricolografia con radionuclidi
  • RNVG
  • Scansione SIMA
  • Scansione di acquisizione multigate sincronizzata
  • Scansione MUGA
  • Scansione di acquisizione multi-gate
  • Scansione del ventricologramma con radionuclidi
  • Scansione del pool cardiaco recintato
  • Scansione RNV

Undergo CT scan

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Given IV

Altri nomi:
  • ATI-0918
  • Celice
  • Doxil
  • Doxilen
  • Doxorubicina HCl liposoma
  • Duomeisu
  • Evacet
  • LipDox
  • Adriamicina liposomiale
  • Doxorubicina incapsulata in liposomi
  • Liposoma doxorubicina HCl pegilato
  • Doxorubicina S-liposomiale
  • Doxorubicina liposomiale invisibile
  • TLC D-99
  • Dox SL
  • Doxorubicina HCl liposomiale
  • Liposoma doxorubicina cloridrato
  • Lipox 50
  • Doxorubicina cloridrato liposomiale
  • Doxorubicina liposomiale pegilata
  • Doxorubicina Liposomiale

Undergo tissue biopsy

Altri nomi:
  • Bx
  • BIOPSY_TYPE
  • Biopsia

Given PO

Altri nomi:
  • MSC2490484A
  • 3-piridazinametanolo, alfa-(2-cloro-4-fluoro-5-(7-(4-morfolinil)-4-chinazolinil)fenil)-6-metossi-, (alfaS)-
  • M3814
  • M-3814
  • MSC 2490484A
  • MSC-2490484A
  • Nedisertib

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Dose limiting toxicity (DLT) rate
Lasso di tempo: Up to 28 days

The number and type of DLT seen at each dose level will be provided. The adverse events (AEs) will also be summarized by AE type and the maximum grade of the AE experienced by the patient for each dose level. DLT will be used to determine the recommended phase 2 dose of study drugs.

Up to 28 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of adverse events
Lasso di tempo: Up to 30 days after the end of study treatment

AEs will be assessed using Common Terminology Criteria for Adverse Events version 5.

Up to 30 days after the end of study treatment
Objective response rate
Lasso di tempo: Up to 28 days

Assessed with Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.

Up to 28 days
Progression free survival
Lasso di tempo: From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Patients who are alive at the time of analysis without a documented disease progression will be censored at the time of their last tumor evaluation.

From study enrollment until disease progression (determined by RECIST v1.1) or death due to any cause, whichever occurs first
Homologous recombination deficiency (HRD) status
Lasso di tempo: Up to 1 year

Will be defined by HRD score and mutational signature analysis.

Up to 1 year
Deoxyribonucleic acid damage repair activity
Lasso di tempo: Up to 1 year

Will be defined by gammaH2AX and NBS1 S343 phosphorylation based on the National Clinical Laboratory Network DDR3 assay.

Up to 1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Candace L Haddox, Dana-Farber - Harvard Cancer Center LAO

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 febbraio 2024

Completamento primario (Stimato)

3 maggio 2027

Completamento dello studio (Stimato)

3 maggio 2027

Date di iscrizione allo studio

Primo inviato

2 febbraio 2023

Primo inviato che soddisfa i criteri di controllo qualità

2 febbraio 2023

Primo Inserito (Effettivo)

3 febbraio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi